Innovator of The Year Nominee for the Orange County Business Journal With over 30 years of brand and product development experience in the nutraceutical, pharmaceutical, and medical device sectors, Edalat founded Vivera to create a pharmaceutical company whose core mission would be to put patients first. His forward-thinking management approach as CEO has seen Vivera Pharmaceuticals grow from a single division at its founding to over six divisions and counting today. Leading Vivera’s business development domestically and internationally, Edalat works closely with Vivera’s sales and marketing teams to anticipate and meet market demands. With trusted global relationships built over the decades, Edalat has worked to leverage his connections and expand Vivera’s reach. In addition, he has led the company through innovative research and development at home.
CEO Visionary – LA Times B2B Publishing C-Suite Magazine As a founding partner, CEO, and chairman of Vivera Pharmaceuticals, Paul Edalat is a visionary industry disruptor driven by his desire to transform the pharmaceutical industry to serve patients and consumers better. Edalat’s mission is to upend an outdated industry to improve the lives and well-being of all Americans regardless of race, socioeconomics, or any other social determinant of health. He is a true believer in the power of future-focused medicine to ensure equitable health opportunities for all. Edalat is dedicated to making a positive difference for vulnerable communities worldwide. When the global pandemic hit in 2020, he knew his team had to step up to help the community. Vivera already had an entire pharmaceutical team that was the perfect fit to help distribute COVID-19 testing. The team wanted to help ease Americans’ anxiety, which started with providing no-cost testing to numerous organizations across the United States.
Excellence in Entreprenuership Nominee for the Orange County Business Journal As a founding partner, CEO, and chairman of Vivera Pharmaceuticals, Paul Edalat is a visionary industry disruptor driven by his desire to transform the pharmaceuticals industry to better serve patients and consumers. Edalat’s mission is to upend an outdated industry to improve the lives and wellbeing of all Americans: regardless of race, socioeconomics, or any other social determinant of health. He is a true believer in the power of future-focused medicine to ensure equitable health opportunities for all. Working with Vivera’s team of scientists, doctors, and advisors, the company is leading the way with innovative new technologies such as its patented ZICOH, a drug delivery device, and the patented TABMELT, sublingual drug delivery system. Together with the team, Edalat leads a whole-patient approach to treatment, focusing on the synergistic roles mental and physical health have together. With the company’s expansion into medical technologies and neurosciences, Edalat wants to bring a fresh new perspective to just how patient care can be achieved.
MedTech Outlook: Top 10 Drug Delivery Solution Providers Paul Edalat discusses the future of ZICOH, a patented, high-tech, electronic, dose-controlled prescription medication delivery system that works seamlessly through the medication supply chain from the manufacturer to the patient to provide a fully integrated solution to prescription drug abuse.
ONdrugDELIVERY: Smart Drug Delivery Devices Improve Medication Adherence: Here’s How Paul Edalat, Chairman, Founder & Chief Executive Officer, and Mehdi Hatamian, PhD, Senior Scientific Advisor & Interim Chief Scientific Officer, both at Vivera Pharmaceuticals, take an in-depth look at medication non-adherence and how technology can be used to improve compliance rates and optimize patient outcomes.
Vivera picks up new patent for electronic dose-controlled drug delivery devices Newport Beach, California–based Vivera’s latest patent from the U.S. Patent and Trademark Office (USPTO) secures Zicoh’s rights as a smart dosing system with automated delivery, measurement, and management for oral format medications, including pills, capsules and tablets.
Vivera gets US patents for Zicoh smart inhaler Within one week in August, Vivera Pharmaceuticals has announced the issuance of two US patents covering its Zicoh smart inhaler technology. The first is US Patent No. 11,083,850 (“Secure smart dosing system with automated delivery, measurement, and management”) and the second is US Patent No. 11,090,449 (“Smart inhaler device with automated dose delivery, measurement, and management”).
Vivera Pharmaceuticals receives US patent for Zicoh Vivera Pharmaceuticals has announced that the US Patent and Trademark Office (USPTO) issued the US Patent No. 11,083,850 for Zicoh, the company’s wireless, electronic and dose-controlled medication-delivery device, according to a company statement.